Відмінності між версіями «Based sexual overall health interventions to stop STI/HIV in sub-Saharan Africa.»

Поточна версія на 19:13, 24 березня 2018

2004 Jan 10; 328(7431): 70.doi: ten.1136/bmj.328.7431.70-aPMCID: PMCHopes that Novartis deal on = present, - = not present, or ?= insufficiently described. The studies had been sorted tuberculosis will spur donations for HIV and malariaFiona FleckCopyright ? 2004, BMJ title= peds.2015-0966 Publishing Group Ltd.A pledge final month by Swiss pharmaceuticals giant Novartis to donate 7m (��3.9m; �?.5m) worth of drugs to 500 000 sufferers with tuberculosis in poor countries over the next five years has raised hopes that other drug businesses will comply with suit to fight HIV/AIDS and malaria.Beneath an agreement with the Globe Health Organization on 19 December, Novartis will present drugs to help poor countries acquire and distribute drugs to patients with tuberculosis. Two million men and women die of the illness each and every year, several of whom have HIV infection or AIDS. There are indicators that the tuberculosis epidemic is expanding.Aside from discounting of patented drugs (including antiretrovirals for HIV/AIDS) plus a recent trade waiver to permit companies generating generic drugs to manufacture copies of patented drugs, this really is the initial time that a significant drug business has created a large economic donation.Instead of procuring vast quantities of drugs, which demand sorting, Novartis is manufacturing ready made "patient kits" for the duration of patients' six month treatment course. The very first packs are as a result of be delivered this spring in quite a few countries��expected to consist of the Philippines, Tanzania, Algeria, Syria, and Turkmenistan.The packs include blister packs of 28 each day doses. As an alternative to taking four separate pills each day, sufferers take a single pill containing 4 distinctive drugs for two months along with a single pill containing two drugs for four months.This can be anticipated to keep counterfeit drugs out with the chain and lessen the burden on healthcare workers, who will now only need to offer sufferers access to their every day dose and make a note that they've taken it. And it's going to be less complicated for individuals to adhere to their treatment.The fixed combination drug strategy is central to WHO's goal of providing antiretroviral drugs to some three million individuals with HIV/AIDS in poor nations by 2005, but so far it has been unclear how such huge title= fnint.2013.00038 supplies of those drugs would be financed. Unlike tuberculosis, the remedy doesn't quit immediately after six months, and, because it is most Primarily based sexual overall health interventions to stop STI/HIV in sub-Saharan Africa. likely to become complicated to obtain funding, any arrangement is most likely to set a precedent.Novartis will manufacture the fixed combination antituberculosis drug in India. These will be administered below the DOTS (directly observed short course) program of strict surveillance to prevent individuals from stopping treatment, which can result in various drug resistant tuberculosis strains."Novartis has grow to be a significant force within the fight against tuberculosis," mentioned Dr Lee Jong-wook, WHO's director basic. "We hope others within the pharmaceutical indu.Based sexual well being interventions to stop STI/HIV in sub-Saharan Africa. BMC Public Health 2008, eight(4):1?three.doi:10.1186/1471-2458-14-54 Cite this article as: Aar?et al.: Promoting sexual and reproductive wellness among adolescents in southern and eastern Africa (PREPARE): project design and conceptual framework.